- Australian biotech with current focus on making standard frontline cancer chemotherapy work more effectively, in more cancers, and with less-damaging side-effects using innovative Australian technology
- $6M raised in over-subscribed IPO
- Clinic-ready company with inaugural product, NOX66, poised to enter human trials.
Noxopharm Limited is pleased to advise shareholders that it commences trading today on the Australian Securities Exchange (“ASX”) at 11 am (AEST) 9 August 2016. This follows a successful Initial Public Offer which raised the target of $6M and closed oversubscribed following strong investor support.
For further information please download PDF attached:
Download this document
